文献速递头颈神经MR

MRI检测的咽后淋巴结预测鼻咽癌结局的最佳大小阈值:一项双中心研究

Optimal Size Threshold for MRI-Detected Retropharyngeal Lymph Nodes to Predict Outcomes in Nasopharyngeal Carcinoma: A Two-Center Study.
PubMed 文献 · AJR Am J Roentgenol · 2023-09-27

这项双中心回顾性研究纳入1752例接受调强放疗的鼻咽癌患者,通过ROC和限制性立方样条分析确定MRI上咽后淋巴结最小轴径预测无进展生存的最佳阈值为6 mm,多因素Cox回归显示最小轴径≥6 mm独立预测无进展生存(HR=1.35,p=.02),且6 mm阈值在分期和疗效预测上优于5 mm阈值。

要点

  • MRI上咽后淋巴结最小轴径≥6 mm独立预测鼻咽癌患者无进展生存(HR=1.35,p=.02)。
  • N1期无颈部淋巴结受累患者中,最小轴径≥6 mm组5年无进展生存77.2%,≥5 mm且<6 mm组89.7%(p=.03)。
  • 6 mm阈值定义的I期和II期患者总生存有显著差异(p=.04),5 mm阈值则无(p=.09)。

核心结论

  • 研究结果支持以最小轴径6 mm作为判断鼻咽癌患者咽后淋巴结受累的阈值。

研究设计与样本

  • 双中心回顾性研究,纳入2010年1月至2014年3月两家医院接受调强放疗的1752例鼻咽癌患者(中位年龄46岁,男1297例、女455例),其中438例治疗后3-4个月接受MRI;两名放射科医生共识测量最大咽后淋巴结最小轴径,第三名放射科医生在260例随机患者中测量以评估观察者间一致性。

诊断标准与关键数值

  • 最小轴径观察者间一致性组内相关系数为0.943;ROC和限制性立方样条分析得出预测无进展生存的最佳阈值为6 mm;最小轴径≥6 mm在多因素分析中独立预测无进展生存:全部患者HR=1.35(p=.02),N0或N1期患者HR=1.80(p=.008),接受治疗后MRI患者HR=1.68(p=.04)。

临床应用与阅片要点

  • 在报告鼻咽癌咽后淋巴结时,可关注最小轴径是否达到6 mm,因其与无进展生存和总生存相关,并可能影响N分期和肿瘤分期判断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Retropharyngeal lymph node (RLN) metastases have profound prognostic implications in patients with nasopharyngeal carcinoma (NPC). However, the AJCC staging system does not specify a size threshold for determining RLN involvement, resulting in inconsistent thresholds in practice. OBJECTIVE. The purpose of this article was to determine the optimal size threshold for determining the presence of metastatic RLNs on MRI in patients with NPC, in terms of outcome predictions. METHODS. This retrospective study included 1752 patients (median age, 46 years; 1297 men, 455 women) with NPC treated by intensity-modulated radiotherapy (RT) from January 2010 to March 2014 from two hospitals; 438 patients underwent MRI 3-4 months after treatment. Two radiologists measured the minimal axial diameter (MAD) of the largest RLN for each patient using a consensus process. A third radiologist measured MAD in 260 randomly selected patients to assess interobserver agreement. Initial ROC and restricted cubic spline (RCS) analyses were used to derive an optimal MAD threshold for predicting progression-free survival (PFS). The threshold's predictive utility was assessed in multivariable Cox regression analyses, controlling for standard clinical predictors. The threshold's utility for predicting PFS and overall survival (OS) was compared with a 5-mm threshold using Kaplan-Meier curves and log-rank tests. RESULTS. The intraclass correlation coefficient for MAD was 0.943. ROC and RCS analyses yielded an optimal threshold of 6 mm. In multivariable analyses, MAD of 6 mm and greater independently predicted PFS in all patients (HR = 1.35, p = .02), patients with N0 or N1 disease (HR = 1.80, p = .008), and patients who underwent posttreatment MRI (HR = 1.68, p = .04). In patients with N1 disease without cervical lymph node involvement, 5-year PFS was worse for MAD greater than or equal to 6 mm than for MAD that was greater than or equal to 5 mm but less than 6 mm (77.2% vs 89.7%, p = .03). OS was significantly different in patients with stage I and stage II disease defined using a 6-mm threshold (p = .04), but not using a 5-mm threshold (p = .09). The 5-year PFS rate was associated with a post-RT MAD of 6 mm and greater (HR = 1.68, p = .04) but not a post-RT MAD greater than or equal to 5 mm (HR = 1.09, p = .71). CONCLUSION. The findings support a threshold MAD of 6 mm for determining RLN involvement in patients with NPC. CLINICAL IMPACT. Future AJCC staging updates should consider incorporation of the 6-mm threshold for N-category and tumor-stage determinations.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Zhu Y, Luo C, Zhou S, et al. Optimal Size Threshold for MRI-Detected Retropharyngeal Lymph Nodes to Predict Outcomes in Nasopharyngeal Carcinoma: A Two-Center Study. AJR Am J Roentgenol. 2023. PMID: 37753859. doi:10.2214/AJR.23.29984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。